Fifteenth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

 

Co-sponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, and the Movement Disorder Society

Was held on Sunday, September 30, 2001 at the Hyatt Regency Chicago, Chicago, Illinois   Thank you to all who attended this Symposia. Details of next year's Symposia are forthcoming.

MORNING SESSION: 8:15 AM - NOON The morning session will focus on the etiology, pathogenesis, and treatment of Parkinson's disease. It consists of a keynote speaker and 10 presentations by the following individuals with allotted time for questions and answers after each presenter.

8:15-9:00 AM KEYNOTE ADDRESS: What Have We Learned About Parkinson's Disease From Recent Experience With Surgery? Anthony E. Lang, MD, FRCPC, University of Toronto, Toronto, Ontario, Canada. 9:00-9:15 AM Earlier Treatment with Rasagiline May Attenuate (UPDRS) Progression of PD. Parkinson Study Group, (A. Siderowf1, presenter). 1University of Pennsylvania, Philadelphia, Pennsylvania. 9:15-9:30 AM Defining Responder Status in a Clinical Trial of the Rotigotine Transdermal System (SPM-962) in Early Parkinson's Disease. Parkinson Study Group, (K.A. Blindauer1, presenter). 1Medical College of Wisconsin, Milwaukee, Wisconsin. 9:30-9:45 AM Effects of Subthalamic Nucleus Stimulation on Motor Cortex Excitability in Parkinson's Disease. D. Cunic, L. Roshan, A. Lozano, A.E. Lang, R. Chen, University of Toronto, Toronto, Ontario, Canada. 9:45-10:00 AM Long-Term Open Label Evaluation of Globus Pallidus Stimulation for the Treatment of Parkinson's Disease. R. Pahwa1, K.E. Lyons2, A.I. Troster3, W.C. Koller2, S.Wilkinson1. 1University of Kansas Medical Center, Kansas City, Kansas, 2University of Miami Medical Center, Miami, Florida, 3University of Washington, Seattle, Washington. 10:00-10:15 AM Clinical Outcome of Bilateral Subthalamic Nucleus Stimulation in Patients with Parkinson's Disease. F.J. Revilla, J.L. Dowling, K.M. Rich, A. Loepker, J.S. Perlmutter, J.W. Mink. Washington University School of Medicine, St. Louis, Missouri. 10:15-10:45 AM BREAK 10:45-11:00 AM Changes in Motor Performance after Human Embryonic Dopamine Cell Transplantation Is Predicted by Pre-Operative Levodopa Response. C.R. Freed1, K. Bjugstad1, R.E. Breeze1, P.E. Greene2, W.Y. Tsai2, R. Kao2, D. Eidelberg3, S. Fahn2. 1University of Colorado School of Medicine, Denver, Colorado, 2Columbia University, New York, New York, 3North Shore University Hospital, Manhasset, New York. 11:00-11:15 AM A Double-Blind, Randomized, Controlled, Multicenter Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Ventral Mesencephalic Cells Versus Imitation Surgery in Patients with Parkinson's Disease. R.A. Hauser1, R.L. Watts2, T.B. Freeman1, R.A. Bakay2, S.A. Ellias3, A.J. Stoessl4, D. Eidelberg5, J.H. Dinsmore6, J.S. Fink3. 1University of South Florida, Tampa, Florida, 2Emory University School of Medicine, Atlanta, Georgia, 3Boston University School of Medicine, Boston, Massachusetts, 4University of British Columbia, Vancouver, British Columbia, Canada, 5North Shore University Hospital, Manhasset, New York, 6Diacrin, Charlestown, Massachusetts. 11:15-11:30 AM Lewy Body Cortical Involvement May Not Always Predict Dementia in Parkinson's Disease. C. Colosimo, A.J. Hughes, S. Daniel, A.J. Lees. Parkinson's Disease Society Brain Research Centre, Institute of Neurology, London, United Kingdom. 11:30-11:45 AM Caffeine Intake and the Risk of Incident Parkinson's Disease: The Framingham Study J.S. Fink1, L.A. Bains1, A. Beiser2, S. Seshadri1, P.A. Wolf1. 1Boston University School of Medicine, Boston, Massachusetts, 2Boston University School of Public Health, Boston, Massachusetts. 11:45-Noon Ubiquitination of a-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease. M.G. Schlossmacher1, H. Shimura1, N. Hattori2, M.P. Frosch1, A. Trockenbacher3, R. Schneider3, Y. Mizuno2, K.S. Kosik1, D.J. Selkoe1. 1Brigham and Women's Hospital, Boston, Massachusetts, 2Juntendo University School of Medicine, Tokyo, Japan, 3University of Innsbruck, Innsbruck, Austria.

AFTERNOON SESSION: 1:30 - 5:00 PM The afternoon session for the discussion of movement disorders other than PD will consist of a keynote address and 8 presentations by the following individuals with allotted time for questions and answers after each presenter.

1:30-2:30 PM KEYNOTE ADDRESS: Neurodegeneration in Parkinson's Disease and Related Disorders: What Has Synuclein Got To Do With It? John Q. Trojanowski, M.D., Ph.D., Center for Neurodegenerative Disease Research, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 2:30-2:45 PM Enhanced sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Transgenic Mouse Model of Huntington's Disease. L.A. Raymond, M.M. Zeron, C.L. Wellington, C. Krebs, B.R. Leavitt, K.G. Baimbridge, M.R. Hayden. University of British Columbia, Vancouver, British Columbia, Canada. 2:45-3:00 PM The Relationship of Immunological and Cognitive Function in Early Stages of Huntington's Disease. S.K. Kostyk, S.L. Rogers, R.A. Bornstein. The Ohio State University, Columbus, Ohio. 3:00-3:15 PM BREAK 3:15-3:30 PM Metabolic Brain Networks in Presymptomatic Huntington's Disease. A. Feigin1, M. Fukuda1, D. Zgaljardic1, V. Dhawan1, M. Guttman2, J.S. Paulsen3, D. Eidelberg1. 1North Shore University Hospital, Manhasset, New York, 2University of Toronto, Ontario, Canada, 3University of Iowa, Iowa City, Iowa. 3:30-3:45 PM A Novel locus for Inherited Myoclonus-Dystonia on 18p11. D. A. Grimes1, P. St. George-Hyslop2, A.E. Lang3, D. E. Bulman1. 1The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 2University of Toronto, Toronto, Ontario, Canada, 3The University Health Network - Toronto Western Hospital, Toronto, Canada. 3:45-4:00 PM H1 Haplotype Is Not a Significant Risk Factor for Phenotypic Presentation in PPND Family (FTDP-17 Kindred With N279K Mutation in the Tau Gene). Y. Tsuboi, M. Baker, R.J. Uitti, M. Hutton, Z.K. Wszolek. Mayo Clinic Jacksonville, Jacksonville, Florida. 4:00-4:15 PM Fragile X Premutation Masquerading As Essential Tremor. M.A. Leehey1, P.J. Hagerman2, F. Tassone2, J. Grigsby1, R. Hagerman2. 1University of Colorado School of Medicine, Denver, Colorado, 2University of California at Davis Medical Center, Sacramento, California. 4:15-4:30 PM Presumed REM Behavior Disorder (RBD) Is Increased in Machado-Joseph Disease (Spinocerebellar Ataxia Type 3). J.H. Friedman. Brown University School of Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island. 4:30-4:45 PM Willingness to Consent for Future Genetic Testing by Individuals at Risk for or with Huntington's Disease: A Preliminary Report. Huntington Study Group, (M.A. Shinaman1, presenter). 1University of Rochester, Rochester, New York.

Posters will be staffed from Noon - 1:30 PM in the Columbus A&B room

Poster 1 (PD) A Multi-Center, Randomized, Double-Blind Pilot Study Comparing TV-1203 and Levodopa Tablets in Advanced Parkinson's Disease Patients with Response Fluctuations. K.A. Blindauer1 and the Parkinson Study Group. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster 2 (PD) Long-Term Effects on Quality of Life among Persons Receiving Fetal Transplant Surgery for Treatment of Parkinson's Disease. C. McRae1, E. Cherin1, G. Diem1, T.G. Yamazaki1, A. Vo1, D. Russell2, H. Ellgring3, S. Fahn4, P.E. Greene4, S. Dillon4, H. Winfield4, L. Winfield4, C. Freed5. 1University of Denver, Denver, Colorado, 2Iowa State University, Ames, Iowa, 3Universitat Wuerzburg, Wuerzburg, Germany, 4Columbia-Presbyterian Medical Center, New York, New York, 5University of Colorado Health Sciences Center, Denver, Colorado. Poster 3 (PD) Do Dopaminergic Complications Predict Quality of Life in Parkinson's Disease? K. Noyes1, J. Zwanziger1, A.W. Dick1, R. Holloway1 and the Parkinson Study Group. 1University of Rochester, Rochester, New York. Poster 4 (PD) Role of DNA Repair in Selective Neuronal Vulnerability to Oxidative Stress. J. Sanchez-Ramos, F. Cardozo-Pelaez, S. Song, T. Stedeford. University of South Florida, Tampa, Florida. Poster 5 (PD) Parkin Facilitates the Degradation of Toxic, Aberrant Proteins. Y.C. Tsai1, G.A. Oyler2, P.S. Fishman2. 1Johns Hopkins University, Baltimore, Maryland, 2University of Maryland School of Medicine, Baltimore, Maryland. Poster 6 (PD) A Qualitative Analysis of Reaching-to-Grasp Movements in Human Parkinson Patients Reveals Impairment in Rotational Movements. O. Suchowersky1, S.M. Pellis2, L. Davis1, J. Sarna1, I.Q. Whishaw2. 1The University of Calgary, Calgary, Alberta, Canada, 2The University of Lethbridge, Lethbridge, Alberta, Canada. Poster 7 (PD) Drug-Induced Psychosis in Parkinsonian Syndromes: Predictors of Quetiapine Non-Response. H.H. Fernandez, M.E. Trieschmann, M.A. Burke, C. Jacques and J.H. Friedman. Brown University School of Medicine, Pawtucket, Rhode Island. Poster 8 (PD) A Small Dose of Levodopa Partially Corrects the Abnormalities in Postexercise Facilitation and Postexercise Depression in Patients with Parkinson's Disease (PD) - A Transcranial Magnetic Stimulation Study. J.S. Lou, T. Benice, G. Kearns, J. Nutt. Oregon Health Sciences University, Portland, Oregon. Poster 9 (PD) Current Opinions on Appropriate Endpoints in Parkinson's Disease-Modifying Trials. J.A. DeMarcaida1, S. Schwid1, K. Blindauer2, S. Fahn3, K. Kieburtz1, K. Marek4, D. Oakes1, M. Stern5, I. Shoulson1 and the Parkinson Study Group. 1University of Rochester, Rochester, New York, 2Medical College of Wisconsin, Milwaukee, Wisconsin, 3Columbia-Presbyterian Medical Center, New York, New York, 4Institute For Neurodegenerative Disorders, New Haven, Connecticut, 5University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania. Poster 10 (PD) Learning by Execution or Imagery in Parkinson's Disease. R. Inzelberg1,2, N. Faeirstein1, P. Nisipeanu1, R.L. Carasso1,2, S. Hocherman2. 1Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel, 2Rappaport Faculty of Medicine, Technion, Haifa, Israel. Poster 11 (PD) Chemotherapy-Induced Parkinsonism Responsive to Levodopa: An Under-Recognized Entity? C. Chuang, A. Constantino, C. Balmaceda, S.J. Frucht. Columbia-Presbyterian Medical Center, New York, New York. Poster 12 (PD) Progression of Parkinson's Disease Following Thalamic Deep Brain Stimulation for Tremor. D. Apetauerova, P. Ryan, D. Mechanic, D. Tarsy. Beth Israel Deaconess Medical Center, Boston, Massachusetts. Poster 13 (PD) Chronic Electrical Stimulation of the Fields of Forel (H1/2) in Parkinson's Disease (PD): Implications for the Mechanism of Deep Brain Stimulation (DBS). R. Kumar, S. Kedia, J.H. McVicker. Colorado Neurological Institute, Englewood, Colorado. Poster 14 (PD) Neurocognitive Dysfunction in a Patient with Familial 4R Tauopathy (PPND) Precedes the Onset of Parkinsonism. C. McRae1, T.J. Ferman2, Z.K. Wszolek2. 1University of Denver, Denver, Colorado, 2Mayo Clinic Jacksonville, Jacksonville, Florida. Poster 15 (PD) Reliability of Self-Reporting Age of Onset for Parkinson's Disease. C.R. Reider1, C.A. Halter2, T. Foroud2, D. Oakes3 and the Parkinson Study Group. 1The Ohio State University, Columbus, Ohio, 2Indiana University, Indianapolis, Indiana, 3University of Rochester, Rochester, New York. Poster 16 (PD) Albuterol Improves Response to Levodopa and Increases Muscle Mass in Parkinson's Disease. E.Y. Uc1*, K.N. Lutz2, S.I. Harik2, W.J. Evans3. 1University of Iowa, Iowa City, Iowa, 2University of Arkansas for Medical Sciences, Little Rock, Arkansas, 3University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, * formerly of University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System. Poster 17 (PD) Depression in Parkinson's Disease: Degree of Association and Rate of Agreement of Clinician-Based and Self-Report Measures. C.R. Cimino1, T.A. Zesiewicz1, E. Soety1, A. Patel1, W.J. Weiner2. 1University of South Florida, Tampa, Florida, 2University of Maryland, Baltimore, Maryland. Poster 18 (PD) Sialorrhea in Parkinson's Disease: Treatment with Ultrasound-Guided Botulinum Toxin Injections. A.V. Nieves1, L. del Rizzo1, A.E. Lang1, D. Muradali2. 1Toronto Western Hospital, University of Toronto, Toronto, Canada, 2Toronto General Hospital, University Health Network, Toronto, Canada. Poster 19 (PD) Therapeutic Effects of Astrocytes Expressing Both Tyrosine Hydroxylase and Brain-Derived Neurotrophic Factor on a Rat Model with Parkinson's Disease. Z.H. Wang1, Y. Ji1, B. Zeng1, W. Shan2, N. Raksadawan1, G.M. Pastores1, E. Ong1, T. Wisniewski1, E.H. Kolodny1. 1New York University School of Medicine, New York, New York, 2Mount Sinai School of Medicine, New York, New York. Poster 20 (Hyperkinetic) Quantitative MRI in Movement Disorders with Memory Change. D.S. Sax1, R. Killiany2, J. Paulsen3, J. Sherman3, P. Chervin3, F. Hussey3. 1Gifford Medical Center, Randolph, Vermont, 2Boston University Medical Center, Boston, Massachusetts, 3MRI Centers of New England, Woburn, Massachusetts. Poster 21 (Hyperkinetic) Youngest Reported Case of Corticobasal Ganglionic Degeneration. A.D. Hohler1, A. Samii2, B.R. Ransom2, M.R. Chun3, A.I. Troster2. 1Madigan Army Medical Center, Tacoma, Washington, 2University of Washington, Seattle, Washington, 3Everett Neurological Center, Seattle, Washington. Poster 22 (Hyperkinetic) Has Tardive Dyskinesia Disappeared? G.W. Paulson. The Ohio State University, Columbus, Ohio. Poster 23 (Hyperkinetic) The Adams Quiveration. G.W. Paulson. The Ohio State University, Columbus, Ohio.

PSG OVERVIEW | PARKINSON'S DISEASE OVERVIEW | WHAT IS A CLINICAL TRIAL CLINICAL TRIALS IN PROGRESS COMPLETED CLINICAL TRIALS | PSG / MDS SYMPOSIA | PUBLICATIONS / ABSTRACTS CONTRIBUTIONS | OTHER USEFUL LINKS   Top of Page